Codelivery of Anticancer Drugs and siRNA By Mesoporous Silica Nanoparticles

Hanafi‐Bojd, Mohammad Yahya; Ansari, Legha; Malaekeh‐Nikouei, Bizhan

doi:10.4155/tde-2016-0045

Cited by 32 publications

(28 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Usually, cationic polyethylenimine (PEI) polymers were absorbed onto the surface of MSNs for condensation of DNA and siRNA. Meanwhile, the polymer attachment leaves the porous interior free for drug binding and delivery, thus establishing the rationale for simultaneous drug and nucleic acid delivery [26, 27]. Indeed, Meng et al have reported that MSN can be functionalized to effectively deliver the chemotherapeutic agent DOX together with anti-P-gp siRNA to a drug-resistant cancer cell line (KB-V1 cells) to accomplish cell killing in an additive or synergistic fashion [49]…”

Section: Combination Of Sirna/chemodrugs In a Single Carriermentioning

confidence: 99%

“…Firstly, amphiphilic polymers can be synthesized to encapsulate multiple hydrophobic drugs through a nanoprecipitation technique [24]. To co-deliver nucleic acid with a hydrophobic drug, cationic, amphiphilic polymers are often used [25–27]. To control the molar ratio of combined drugs with diverse properties in a single formulation, a polymer-drug conjugate presents the best option [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nanoformulations for combination or cascade anticancer therapy

Miao

Guo

Lin

et al. 2017

Advanced Drug Delivery Reviews

148

View full text Add to dashboard Cite

Nanoparticle drug formulations have been extensively investigated, developed, and in some cases, approved by the Food and Drug Administration (FDA). Synergistic combinations of drugs having distinct tumor-inhibiting mechanisms and non-overlapping toxicity can circumvent the issue of treatment resistance and may be essential for effective anti-cancer therapy. At the same time, co-delivery of a combined regimen by a single nanocarrier presents a challenge due to differences in solubility, molecular weight, functional groups and encapsulation conditions between the two drugs. This review discusses cellular and microenvironment mechanisms behind treatment resistance and nanotechnology-based solutions for effective anti-cancer therapy. Co-loading or cascade delivery of multiple drugs using of polymeric nanoparticles, polymer-drug conjugates and lipid nanoparticles will be discussed along with lipid-coated drug nanoparticles developed by our lab and perspectives on combination therapy.

show abstract

Section: Combination Of Sirna/chemodrugs In a Single Carriermentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Nanoformulations for combination or cascade anticancer therapy

Miao

Guo

Lin

et al. 2017

Advanced Drug Delivery Reviews

148

View full text Add to dashboard Cite

show abstract

“…The successful application of siRNA delivery to desired cells or tissues remains challenging due to its negative charge and hydrophilic structure (incompatible with cell membrane), small size (effective clearing from the body), poor stability, and low bioavailability . Moreover, naked siRNA that is intravenously administrated has short serum half‐life ( t 1/2 ) due to the renal clearance and instant degradation by serum nuclease.…”

Section: Introductionmentioning

confidence: 99%

“…A variety of different packaging schemes have been developed such as polymers, liposomes, hydrogels, dendrimers, or inorganic host systems. [6c,7]…”

Section: Introductionmentioning

confidence: 99%

“…MSNs showed unique features, including thermal and chemical stability, biocompatible and nontoxic, large pore volume and high surface area. [6a,8] Furthermore, MSN‐based drug delivery systems can be easily designed to respond to external or internal stimuli, such as pH, light, magnetic field, and enzyme . So far, there are two ways to deliver siRNA to target cells through the aid of MSNs: attachment at the outer surface or encapsulation into the pores of mesoporous silica nanoparticles.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Multifunctional Nanoplatform against Multidrug Resistant Cancer: Merging the Best of Targeted Chemo/Gene/Photothermal Therapy

Cheng

Nie

Gao

et al. 2017

Adv Funct Materials

278

155

View full text Add to dashboard Cite

Synergistic therapy that combines chemo-, gene-, or photothermal means shows great potential for enhancing the therapeutic effects on cancers. Tumor-targeted nanoparticles based on a doxorubicin (DOX)-gated mesoporous silica nanocore (MSN) encapsulated with permeability glycoprotein (P-gp) small interfering RNA (siRNA) and a polydopamine (PDA) outer layer for DOX loading and folic acid decoration are designed. The multifunctional nanoplatform tactfully integrates chemo-(DOX), gene-(P-gp siRNA), and photothermal (PDA layer) substances in one system. In vitro results reveal that DOX release behaviors are both pH-and thermal-responsive and the release of co-delivered P-gp siRNA is also pH-dependent due to the pH-cleavable DOX gatekeeper on MSN. In addition, due to the near-infrared light-responsive PDA outer layer and folic acid conjugation, the nanoparticles exhibit outstanding photothermal activity and selective cell targeting ability. Subsequently, in vitro and in vivo antitumor experiments both demonstrate the enhanced antitumor efficacy of the multifunctional nanoparticles, indicating the significance of synergistic therapy combining chemo-, gene-, and photothermal treatments in one system. Cancer Therapy

show abstract

Curcumin‐based nanoformulations alleviate wounds and related disorders: A comprehensive review

et al. 2023

Self Cite

View full text Add to dashboard Cite

Despite numerous advantages, curcumin's (CUR) low solubility and low bioavailability limit its employment as a free drug. CUR‐incorporated nanoformulation enhances the bioavailability and angiogenesis, collagen deposition, fibroblast proliferation, reepithelization, collagen synthesis, neovascularization, and granulation tissue formation in different wounds. Designing nanoformulations with controlled‐release properties ensure the presence of CUR in the defective area during treatment. Different nanoformulations encompassing nanofibers, nanoparticles (NPs), nanospray, nanoemulsion, nanosuspension, nanoliposome, nanovesicle, and nanomicelle were described in the present study comprehensively. Moreover, for some other systems which contain nano‐CUR or CUR nanoformulations, including some nanofibers, films, composites, scaffolds, gel, and hydrogels seems the CUR‐loaded NPs incorporation has better control of the sustained release, and thereby, the presence of CUR until the final stages of wound healing is more possible. Incorporating CUR‐loaded chitosan NPs into nanofiber increased the release time, while 80% of CUR was released during 240 h (10 days). Therefore, this system can guarantee the presence of CUR during the entire healing period. Furthermore, porous structures such as sponges, aerogels, some hydrogels, and scaffolds disclosed promising performance. These architectures with interconnected pores can mimic the native extracellular matrix, thereby facilitating attachment and infiltration of cells at the wound site, besides maintaining a free flow of nutrients and oxygen within the three‐dimensional structure essential for rapid and proper wound healing, as well as enhancing mechanical strength.

show abstract

Codelivery of Anticancer Drugs and siRNA By Mesoporous Silica Nanoparticles

Cited by 32 publications

References 53 publications

Nanoformulations for combination or cascade anticancer therapy

Nanoformulations for combination or cascade anticancer therapy

A Multifunctional Nanoplatform against Multidrug Resistant Cancer: Merging the Best of Targeted Chemo/Gene/Photothermal Therapy

Curcumin‐based nanoformulations alleviate wounds and related disorders: A comprehensive review

Contact Info

Product

Resources

About